Hemorrhage Information and Courses from MediaLab, Inc.

Samples from patients who have suffered a subarachnoid hemorrhage or cerebral hemorrhage may have a pink- to yellow-tinged supernatant when the sample is centrifuged within one hour after collection. The term used to describe the colored supernatant is xanthochromia. The color varies according to the substance causing the color and the length of time after the incident that the sample is examined.

Monocytes are also present in this field. Increased numbers of monocytes may be seen in chronic bacterial meningitis, multiple sclerosis, fungal meningitis, CNS malignant disorders or CNS hemorrhage.

This course began with a discussion on homeostasis, the body’s desire to maintain a status of physiological equilibrium. Our inborn system of chemical checks and balances, activators and inhibitors, can be disrupted by numerous factors, two of the more common being acquired disease states and disorders passed on to offspring via inheritance. In regard to coagulation, both disease status and genetics can adversely affect the functionality of many hemostatic processes. Impaired hemostatic mechanisms, be it acquired in cases of disease or inherent, may result in situations of either hemorrhage or thrombosis. A situation of hemorrhage, or bleeding external to the vasculature, most often stems from physical vessel trauma, but may also arise from a wide variety of disease states. Thrombosis does not require physical trauma, and is the activation of hemostatic processes at an inappropriate time in an inappropriate place, and may arise from a number of inherited or acquired disease states. The following pages are intended to serve as an introduction to some of the more commonly encountered coagulation disorders.

The first specific PGx testing application most labs are likely to encounter is that used in patients taking warfarin. Recent studies have revealed that the variations seen in patients taking the anticoagulant warfarin are due to PGx factors. The consequences of incorrect warfarin dosing are obviously serious, with inadequate doses predisposing patients to thrombosis and higher doses placing them at risk for hemorrhage. The United States' Food and Drug Administration (FDA) recently approved updated labeling for Coumadin (warfarin sold by Bristol-Myers Squibb). The new labeling suggests that physicians incorporate PGx information into warfarin-dosing regimens for patients. Manufacturers of generic warfarin products are now adding similar labeling.